Efficacy of Platelet-rich Plasma (PRP) in the Treatment of Dark Circles Under the Eyes
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03114514 |
Recruitment Status :
Completed
First Posted : April 14, 2017
Last Update Posted : May 16, 2017
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Periorbital Hyperpigmentation | Biological: PRP | Not Applicable |
Background:
Dark circles around the eyes is a common problem pretending with relatively dark eyelids concerns many patients, especially women, because of the inconvenience caused by esthetic and negative impact on the psyche and the patient's quality of life. There are several causing factors (such as sun exposure, smoking, alcohol, sleep deprivation, genetic and structural factors). variety of treatments have been used for this situation , but without clear results.
The term 'Platelet-Rich Plasma (PRP)' is a general term used to describe hanging plasma that has been obtained from whole blood with concentration of platelets higher than normal concentration found in the circulating blood. PRP's work mechanism depends on the fact that platelets contain important substances called (growth factors), which have a known role in the process of reform and renewal of tissues.
Aim of the research:
This study was designed to evaluate the effectiveness of (PRP) injection in the treatment of dark circles under the eyes. This is an uncontrolled open therapeutic trial study which will be performed at the Hospital of Dermatology and Venereology of Damascus University in Damascus, Syria during the period from June 2016 to June 2017.
The results will be assessed by standardized digital photography month after each injection and three months after the latest assessment with the assistant of skin colors scale. In addition, the patient's satisfaction with the results and any treatment-related side effects will be recorded.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 40 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Efficacy of Platelet-Rich Plasma (PRP) in the Treatment of Periorbital Hyperpigmentation |
Actual Study Start Date : | June 17, 2016 |
Actual Primary Completion Date : | April 20, 2017 |
Actual Study Completion Date : | May 10, 2017 |
Arm | Intervention/treatment |
---|---|
Experimental: PRP injection
A PRP-injection will be performed three times during the course of treatment
|
Biological: PRP
PRP will be injected subcutaneously around the eyes at three different time points with one-month interval
Other Name: platelet-rich plasma |
- Change in Skin Color [ Time Frame: Color shade will be measured at one month following the first injection (T1) and at three months following the third injection (T2) ]Standardized digital photographs will be taken and a color scale will be used
- Satisfaction [ Time Frame: Satisfaction will be measured at three months following the last injection. ]Patients' satisfaction will be measured on a visual analog scale (VAS)

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 15 Years to 65 Years (Child, Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients with periorbital hyperpigmentation
Exclusion Criteria:
- patients with known platelet dysfunction syndrome
- patients with platelet count less than 100,000 ul
- patient with hemodynamic instability
- patients with severe systemic illness or malignancy or chronic medical illness (e.g. diabetes, chronic infections, and blood dyscrasias).
- patients with local skin disorders or active herpes infection at the site of the procedure.
- patients on anti-coagulants therapy or non-steroidal anti-inflammatory drugs (NSAID) within 48 hours of procedure,
- patients with corticosteroid injection at treatment site within 1 month, systemic use of corticosteroids within 2 weeks
- patients with recent fever or illness, and hemoglobin level< 10 g/dl.
- pregnancy
- history of keloidal scarring.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03114514
Syrian Arab Republic | |
Department of Dermatology and Venereology at Damascus University | |
Damascus, Syrian Arab Republic, DM20AM18 |
Principal Investigator: | Raed Sameer Noueihed, M.D. | Resident at the Dermatology and venereology Hospital of Damascus university. |
Responsible Party: | Damascus University |
ClinicalTrials.gov Identifier: | NCT03114514 |
Other Study ID Numbers: |
UDMS-Dermat-01-2017 |
First Posted: | April 14, 2017 Key Record Dates |
Last Update Posted: | May 16, 2017 |
Last Verified: | May 2017 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Hyperpigmentation Pigmentation Disorders Skin Diseases |